Abstract |
Peptide antigens available for use in specific immunotherapy of patients with cancer have not been fully determined. Although the authors have reported the SART1 gene encoding epitopes recognized by HLA-A2601-restricted and tumor-specific cytotoxic T lymphocytes (CTLs), the HLA-A26 allele is mainly subdivided into A2601, A2602, and A2603 subtypes. In this study, the authors attempted to determine whether the SART1-derived peptide at position 736-744 (KGSGKMKTE) is suitable to induce HLA-A26-restricted and tumor-specific CTLs in patients with cancer who have these subtypes. This peptide induced the HLA-A26 subtype-restricted and tumor-specific CTLs in HLA-A2601+ or HLA-A2603+ peripheral blood mononuclear cells, respectively. It also induced the HLA-A26-restricted CTL activity in HLA-A2602+ peripheral blood mononuclear cells. Therefore, this peptide could be useful for specific immunotherapy of patients with cancer who have any of the three HLA-A26 subtypes.
|
Authors | Y Inoue, M Nakao, K Matsunaga, M Kikuchi, S Gomi, U Toh, S Takamori, H Yamana, K Itoh |
Journal | Journal of immunotherapy (Hagerstown, Md. : 1997)
(J Immunother)
2000 May-Jun
Vol. 23
Issue 3
Pg. 296-303
ISSN: 1524-9557 [Print] United States |
PMID | 10838658
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antigens, Neoplasm
- HLA-A Antigens
- HLA-A*26 antigen
- Neoplasm Proteins
- Peptides
- Ribonucleoproteins, Small Nuclear
- SART1 protein, human
|
Topics |
- Antigens, Neoplasm
(immunology)
- Cytotoxicity Tests, Immunologic
- HLA-A Antigens
- Humans
- Neoplasm Proteins
- Neoplasms
(immunology)
- Peptides
(immunology)
- Ribonucleoproteins, Small Nuclear
- T-Lymphocytes, Cytotoxic
(immunology)
|